Our team is best known for a series of controlled, randomized clinical trials that have helped to establish the efficacy of cognitive-behavioral therapy for patients with atypical and recurrent major depressive disorder. We completed a randomized clinical trial which evaluated the long-term efficacy of continuation phase cognitive therapy (C-CT) in preventing depressive relapse and recurrence compared to Prozac (fluoxetine) and pill placebo (both used as continuation phase treatments for cognitive therapy responders). The results can be found here. In collaboration with Michael Thase, M.D. at the University of Pennsylvania, this NIMH-funded study enabled us to develop the largest known dataset in the world of its kind on the effects of cognitive therapy for depressed patients. We continue to explore the data for new insights, and previous reports can be found here under publications.
The team was funded by the NIMH to conduct a study, Preventing Perinatal Depression (PRE-D), to develop tools to prevent depression in at risk (i.e., at least one previous depressive episode) women who are attempting conception or pregnant. Because women with a history of depression have an increased chance of getting depressed again, useful and convenient ways to detect, monitor, and prevent depressive symptoms are needed. The study is accepting referrals and described in more detail here.